The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis

Critical Care Medicine

Volumn 42, Issue 7, 2014, Pages

  Maybauer, Marc O ^a,b   Maybauer, Dirk M ^a,b   Enkhbaatar, Perenlei ^a   Laporte, Régent ^c   Winiewska, Halina ^c   Traber, Lillian D ^a   Lin, Chiidean ^d   Fan, Juanjuan ^d   Hawkins, Hal K ^a   Cox, Robert A ^a   Winiewski, Kazimierz ^c   Schteingart, Claudio D ^c   Landry, Donald W ^e   Rivière, Pierre J M ^c   Traber, Daniel L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Ferring Pharmaceuticals AS   (Denmark)

^d SAN DIEGO STATE UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

capillary leak syndrome; sepsis; vasoconstrictor agents; vasopressins

Indexed keywords

ARGIPRESSIN; DESMOPRESSIN; FE 202158; PROTEIN; RINGER LACTATE SOLUTION; SELEPRESSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSISTED VENTILATION; CAPILLARY LEAK SYNDROME; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MARKER; EXPERIMENTAL SHEEP; FEMALE; FLUID BALANCE; FLUID RESUSCITATION; HEMATOCRIT; LEUKOCYTE; MEAN ARTERIAL PRESSURE; NEUTROPHIL; NONHUMAN; ONCOTIC PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RESUSCITATION; SEPSIS; SHEEP; SURVIVAL; SYSTEMIC VASCULAR RESISTANCE; SYSTEMIC VASCULAR RESISTANCE INDEX; TRACHEOSTOMY; VASCULAR LEAK SYNDROME;

ANIMALS; ARGININE VASOPRESSIN; DRUG THERAPY, COMBINATION; HEMODYNAMICS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; RANDOM ALLOCATION; RECEPTORS, VASOPRESSIN; RESPIRATORY MECHANICS; SEPSIS; SHEEP; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84902551843     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000300     Document Type: Article

References (49)

1. Angus DC, Pereira CA, Silva E: Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006; 6:207-212
2. Yende S, Angus DC: Long-term outcomes from sepsis. Curr Infect Dis Rep 2007; 9:382-386
3. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
4. Rivers E: The outcome of patients presenting to the emergency department with severe sepsis or septic shock. Crit Care 2006; 10:154
5. Huang DT, Clermont G, Dremsizov TT, et al; ProCESS Investigators: Implementation of early goal-directed therapy for severe sepsis and septic shock: A decision analysis. Crit Care Med 2007; 35:2090-2100
6. Jacobson JR, Garcia JG: Novel therapies for microvascular permeability in sepsis. Curr Drug Targets 2007; 8:509-514
7. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
8. Daveu C, Servy C, Dendane M, et al: Oxidation and nitration of catecholamines by nitrogen oxides derived from nitric oxide. Nitric Oxide 1997; 1:234-243
9. Takakura K, Taniguchi T, Muramatsu I, et al: Modification of alpha1-Adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002; 30:894-899
10. Takakura K, Xiaohong W, Takeuchi K, et al: Deactivation of norepinephrine by peroxynitrite as a new pathogenesis in the hypotension of septic shock. Anesthesiology 2003; 98:928-934
11. Sun Q, Dimopoulos G, Nguyen DN, et al: Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003; 168:481-486
12. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125
13. Sharshar T, Blanchard A, Paillard M, et al: Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758
14. Jochberger S, Dörler J, Luckner G, et al: The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 2009; 37:476-482
15. Sharshar T, Carlier R, Blanchard A, et al: Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30:497-500
16. Oliver JA, Landry DW: Endogenous and exogenous vasopressin in shock. Curr Opin Crit Care 2007; 13:376-382
17. Farand P, Hamel M, Lauzier F, et al: Review article: Organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis. Can J Anaesth 2006; 53:934-946
18. Barrett LK, Singer M, Clapp LH: Vasopressin: Mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35:33-40
19. Russell JA: Vasopressin in septic shock. Crit Care Med 2007; 35:S609-S615
20. Russell JA: Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care 2007; 13:383-391
21. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
22. Howl J, Wheatley M: Molecular pharmacology of V1a vasopressin receptors. Gen Pharmacol 1995; 26:1143-1152
23. Barberis C, Mouillac B, Durroux T: Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998; 156:223-229
24. Jard S: Vasopressin receptors. A historical survey. Adv Exp Med Biol 1998; 449:1-13
25. Oshikawa S, Tanoue A, Koshimizu TA, et al: Vasopressin stimulates insulin release from islet cells through V1b receptors: A combined pharmacological/ knockout approach. Mol Pharmacol 2004; 65:623-629
26. Ring RH: The central vasopressinergic system: Examining the opportunities for psychiatric drug development. Curr Pharm Des 2005; 11:205-225
27. Caldwell HK: Oxytocin and vasopressin: Genetics and behavioral implications. Neurochem Mol Neurobiol 2008; 27:1-35
28. Maybauer MO, Maybauer DM, Enkhbaatar P, et al: Physiology of the vasopressin receptors. Best Pract Res Clin Anaesthesiol 2008; 22:253-263
29. Aki Y, Tamaki T, Kiyomoto H, et al: Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. J Cardiovasc Pharmacol 1994; 23:331-336
30. Kaufmann JE, Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1:682-689
31. Knepper MA: Molecular physiology of urinary concentrating mechanism: Regulation of aquaporin water channels by vasopressin. Am J Physiol 1997; 272:F3-F12
32. Laporte R, Kohan A, Heitzmann J, et al: Pharmacological characterization of FE 202158, a novel, potent, selective, and short-Acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther 2011; 337:786-796
33. Wisniewski K, Galyean R, Tariga H, et al: New, potent, selective, and short-Acting peptidic V1a receptor agonists. J Med Chem 2011; 54:4388-4398
34. Murakami K, Bjertnaes LJ, Schmalstieg FC, et al: A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med 2002; 30:2083-2090
35. Maybauer DM, Maybauer MO, Traber LD, et al: Effects of severe smoke inhalation injury and septic shock on global hemodynamics and microvascular blood flow in sheep. Shock 2006; 26:489-495
36. Traber DL: Selective V1a receptor agonists in experimental septic shock. Crit Care 2007; 11:P51
37. Lange M, Traber DL, Enkhbaatar P: The authors reply. Crit Care Med 2011; 40:356-357
38. Maybauer DM, Talke PO, Westphal M, et al: Positive end-expiratory pressure ventilation increases extravascular lung water due to a decrease in lung lymph flow. Anaesth Intensive Care 2006; 34:329-333
39. Yesberg NE, Henderson M, Budtz-Olsen OE: The effects of two analogues of arginine-vasopressin (ornithine-vasopressin and desamino-d-Arginine-vasopressin) on kidney function in sheep. Q J Exp Physiol Cogn Med Sci 1978; 63:179-188
40. Stegner H, Artman HG, Leake RD, et al: DDAVP ( 1-desamino-8-d-Arginine vasopressin) clearance rate. Acta Endocrinol (Copenh) 1984; 107:204-206
41. Stegner H, Leake RD, Palmer SM, et al: Arginine vasopressin metabolic clearance and production rates in fetal sheep, pregnant ewes, and lambs. Dev Pharmacol Ther 1984; 7:87-93
42. Enkhbaatar P, Murakami K, Traber LD, et al: The inhibition of inducible nitric oxide synthase in ovine sepsis model. Shock 2006; 25:522-527
43. Nakano Y, Maybauer MO, Maybauer DM, et al: A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock. Burns 2010; 36:1050-1058
44. Rehberg S, Ertmer C, Vincent JL, et al: Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med 2011; 39:119-125
45. Rehberg S, Yamamoto Y, Sousse LE, et al: Selective V1a agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol 2012; 303:H1245-H1254
46. Enkhbaatar P, Joncam C, Traber L, et al: Novel ovine model of methicillin-resistant Staphylococcus aureus-induced pneumonia and sepsis. Shock 2008; 29:642-649
47. Vincent JL, Sakr Y, Sprung CL, et al; Sepsis Occurrence in Acutely Ill Patients Investigators: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34:344-353
48. Payen D, de Pont AC, Sakr Y, et al; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators: A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12:R74
49. Boyd JH, Forbes J, Nakada TA, et al: Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 39:259-265